2017
Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?
Adam LC, Murali N, Chapiro J, Geschwind JF. Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet? Radiology 2017, 285: 333-335. PMID: 29045226, PMCID: PMC5673055, DOI: 10.1148/radiol.2017171527.Peer-Reviewed Original ResearchConceptsRadiofrequency ablationRF ablationHepatocellular carcinoma mouse modelTechnical success rateSurvival end pointsChemotherapeutic drug concentrationsCarcinoma mouse modelAnimal tumor modelsTumor-penetrating peptideClinical outcomesTarget lesionsDrug delivery systemsLiver cancerMouse modelTumor modelEnd pointDrug concentrationsDrug deliverySuccess rateTumor treatmentToxic effectsDelivery systemAblationMagic bulletLesions
2015
3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma
Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. European Radiology 2015, 26: 849-857. PMID: 26139318, PMCID: PMC4698362, DOI: 10.1007/s00330-015-3895-9.Peer-Reviewed Original ResearchConceptsSingle-session stereotactic radiosurgeryTotal tumor volumeSignificant tumor shrinkageVestibular schwannomaTumor shrinkageStereotactic radiotherapyTumor volumeRadiation therapyStereotactic radiosurgeryT1-weighted contrast-enhanced MRISubsequent microsurgical resectionTumor-related symptomsSporadic vestibular schwannomaContrast-enhanced MRIFSRT groupRadiological progressionMicrosurgical resectionClinical outcomesSRS groupRetrospective analysisResponse assessmentPatientsVolumetric assessmentFSRTSchwannoma
2014
Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit?
Chapiro J, Duran R, Geschwind JF. Combination of intra-arterial therapies and sorafenib: Is there a clinical benefit? La Radiologia Medica 2014, 119: 476-482. PMID: 24894921, DOI: 10.1007/s11547-014-0413-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticEmbolization, TherapeuticHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsMicrospheresNeoplasm StagingNiacinamidePhenylurea CompoundsRadiography, InterventionalSorafenibSurvival RateConceptsIntra-arterial therapySurvival benefitIntroduction of sorafenibLoco-regional approachesAdvanced stage diseaseSignificant survival benefitUnresectable hepatocellular carcinomaLocal tumor controlTreatment of patientsSequence of administrationConventional systemic chemotherapyInternational clinical trialsOral monotherapySystemic chemotherapyExciting new optionsClinical outcomesTransarterial chemoembolizationClinical benefitSafety profileTumor controlClinical trialsHepatocellular carcinomaNovel agentsPotential biomarkersSystemic toxicity